Head-to-head evidence
ENV-501 vs Patritumab Deruxtecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline
ENV-501
Developed by Hummingbird Bioscience
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT06956690 (registry estimate)
Patritumab Deruxtecan
Developed by Daiichi Sankyo and partners
NCT05865990 · Phase 2 · completed
The study used a single-arm, open-label design with no placebo or active comparator, so responses cannot be reliably separated from the natural course of disease or other factors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: September 2027 · NCT06172478 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ENV-501's landscape · Patritumab Deruxtecan's landscape